These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39212236)

  • 1. Nanobody-based heavy chain antibodies and chimeric antibodies.
    Koch-Nolte F
    Immunol Rev; 2024 Aug; ():. PubMed ID: 39212236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction to heavy chain antibodies and derived Nanobodies.
    Vincke C; Muyldermans S
    Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools.
    Liu B; Yang D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibody.
    Ahmadvand D; Rahbarizadeh F; Vishteh VK
    Hybridoma (Larchmt); 2008 Aug; 27(4):269-76. PubMed ID: 18707545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single domain antibody: Development and application in biotechnology and biopharma.
    Yu T; Zheng F; He W; Muyldermans S; Wen Y
    Immunol Rev; 2024 Aug; ():. PubMed ID: 39166870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
    Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG
    Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of heavy-chain antibody gene repertoires in Bactrian camels.
    Liu Y; Yi L; Li Y; Wang Z; Jirimutu
    J Genet Genomics; 2023 Jan; 50(1):38-45. PubMed ID: 35500746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
    Hambach J; Mann AM; Bannas P; Koch-Nolte F
    Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camelid immunoglobulins and nanobody technology.
    Muyldermans S; Baral TN; Retamozzo VC; De Baetselier P; De Genst E; Kinne J; Leonhardt H; Magez S; Nguyen VK; Revets H; Rothbauer U; Stijlemans B; Tillib S; Wernery U; Wyns L; Hassanzadeh-Ghassabeh G; Saerens D
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):178-83. PubMed ID: 19026455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application Progress of the Single Domain Antibody in Medicine.
    Tang H; Gao Y; Han J
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies.
    Saerens D
    World J Biol Chem; 2010 Jul; 1(7):235-8. PubMed ID: 21537479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
    Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
    Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.
    Ji F; Ren J; Vincke C; Jia L; Muyldermans S
    Methods Mol Biol; 2022; 2446():3-17. PubMed ID: 35157266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of nanobodies in plant science and biotechnology.
    Wang W; Yuan J; Jiang C
    Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
    Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2559. PubMed ID: 30459772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Antibody and Nanobody Tools for P2X7.
    Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
    Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.